Displaying 341 - 360 of 683
FTC Approves Final Order Requiring Canadian Fertilizer and Chemical Companies PotashCorp and Agrium to Divest 2 Production Facilities as Condition of Merger
FTC Approves Final Order Requiring Divestiture of 2 Medical Device Product Lines as Condition of Becton, Dickinson and Company Acquiring C. R. Bard, Inc.
FTC Requires Divestitures as Condition of 7-Eleven, Inc. Parent Company’s $3.3 Billion Acquisition of Nearly 1,100 Retail Fuel Outlets from Competitor Sunoco
FTC Approves Final Order Requiring Alimentation Couche-Tard Inc. to Divest Three Retail Fuel Station and Convenience Stores in Alabama
FTC Requires Canadian Fertilizer and Chemical Companies PotashCorp and Agrium to Divest 2 Production Facilities as Condition of Merger
FTC Requires Divestiture of Two Medical Device Product Lines as Condition of Becton, Dickinson and Company Acquiring C. R. Bard, Inc.
FTC Approves Final Order Preserving Competition in Markets for Five Types of Medical Devices
FTC Challenges Consummated Merger of Companies That Make Microprocessor Prosthetic Knees
FTC Alters Final Consent Order in Response to Public Comments, Preserving Competition for Specialty and Emergency Veterinary Services in 10 U.S. Localities
FTC Requires Retail Fuel Station and Convenience Store Operator Alimentation Couche-Tard Inc. and its affiliate CrossAmerica Partners LP to Divest 10 Fuel Stations in Minnesota and Wisconsin as a Condition of Acquiring Holiday Companies
Statement by Federal Trade Commission Acting Bureau of Competition Director Bruce Hoffman on the Court Ruling Granting a Preliminary Injunction in the Sanford Health/Mid Dakota Clinic Matter
FTC Challenges Proposed Merger of Major Titanium Dioxide Companies
FTC Requires Retail Fuel Station and Convenience Store Operator Alimentation Couche-Tard Inc. to Divest 3 Fuel Stations in Alabama as a Condition of Acquiring Jet-Pep, Inc.
FTC Approves Final Order Preserving Competition in the U.S. Markets for Two Types of Medical Testing Devices
Parties Agree to Divestiture of Senior Living Facilities Referral Service Caring.com as a Condition of Red Venture’s Acquiring Bankrate
FTC Seeks Public Comment on Fresenius Medical Care AG’s Application for Approval of Proposed Plan to Establish New Outpatient Hemodialysis Clinic
Statement of Acting Chairman Maureen K. Ohlhausen In Walgreens Boots Alliance/Rite Aid
Grifols, S.A., and Talecris Biotherapeutics Holdings Corp., In the Matter of
The FTC required Grifols, S.A., a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire a leading plasma-derived drug manufacturer, Talecris Biotherapeutics Holdings Corp. It resolves FTC charges that Grifols’ proposed acquisition of Talecris would be anticompetitive and would violate federal antitrust laws. As part of the settlement, Grifols will sell the Talecris fractionation facility in Melville, New York, and Grifols’ plasma collection centers in Mobile, Alabama, and Winston-Salem, North Carolina, to Kedrion S.p.A. Kedrion is a manufacturer of plasma-derived products in Europe and other markets, and will be a new entrant in the U.S. plasma-derived products industry. Grifols also will manufacture three plasma-derived products for Kedrion for several years under a manufacturing agreement. The FTC approved a final order on July 22, 2011.
Displaying 341 - 360 of 683